Formulation, characterization and permeability study of nano particles of lipo-endomorphin-1 for oral delivery

Journal of Liposome Research

Volumn 23, Issue 4, 2013, Pages 311-317

  Eskandari, Sharareh ^a   Varamini, Pegah ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Endomorphin 1; Eudragit S100; Lipoamino acid; Oral delivery; Peptide delivery; Solid lipid nanoparticle

Indexed keywords

ENDOMORPHIN 1; EUDRAGIT; LIPOENDOMORPHIN 1; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; HUMAN CELL; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OLIGOPEPTIDES; PARTICLE SIZE; PERMEABILITY;

EID: 84885452702     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2013.805339     Document Type: Article

References (60)

1. Allémann E, Leroux JC, Gurny R. (1998). Polymeric nano-and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 34:171-89. (Pubitemid 28535111)
2. Amidon GL, Lennernäs H, Shah VP, Crison J. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceut Res 12:413-20.
3. Avdeef A. (2007). Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev 59:568-90. (Pubitemid 47285405)
4. Barea MEJ. (2012). An investigation into liposomal formulations for targeted drug delivery to the colon. UK: University of Birmingham.
5. Barea M, Jenkins M, Gaber M, Bridson R. (2010). Evaluation of liposomes coated with a pH responsive polymer. Int J Pharmaceut 402:89-94.
6. Bouchemal K, Briançon S, Perrier E, Fessi H. (2004). Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharmaceut 280:241-51. (Pubitemid 38960674)
7. Brockman H. (2000). Kinetic behavior of the pancreatic lipase-colipaselipid system. Biochimie 82:987-95.
8. Cetin M, Aktas MS, Vural I, Ozturk M. (2012). Salmon calcitoninloaded Eudragit and Eudragit-PLGA nanoparticles: in vitro and in vivo evaluation. J Microencapsul 29:156-66.
9. Czapla MA, Gozal D, Alea OA, et al. (2000). Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. Am J Respirat Crit Care Med 162:994-9.
10. Delie F, Blanco-prieto MJ. (2005). Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10:65-80. (Pubitemid 40404886)
11. des rieux A, Fievez V, Garinot M, et al. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Rel 116:1-27. (Pubitemid 44792295)
12. Dogru S, Calis S, Öner F. (2001). Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro-in vivo evaluation. J Clin Phar Therapeut 25:435-43. (Pubitemid 32055601)
13. El-kamel AH, Sokar MS, Al gamal SS, Naggar VF. (2001). Preparation and evaluation of ketoprofen floating oral delivery system. Int J Pharmaceut 220:13-21. (Pubitemid 32476837)
14. Eratalay A, Öner F, Özcengiz E, Alpar R. (2004). Adjuvant effects of niosome and water/oil/water multiple emulsion carrier systems for recombinant hepatitis b surface antigen. Hacettepe University. J Faculty Pharm 24:81-94.
15. Gupta H, Sharma A. (2009). Recent trends in protein and peptide drug delivery systems. Asian J Pharmaceut 3:69-75.
16. Hamman JH, Enslin GM, Kotze AF. (2005). Oral delivery of peptide drugs: barriers and developments. BioDrugs 19:165-77. (Pubitemid 40994232)
17. Hu F, Yuan H, Zhang H, Fang M. (2002). Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharmaceut 239:121-8.
18. Iwanaga K, Ono S, Narioka K, et al. (1999). Application of surfacecoated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J Pharmaceut Sci 88: 248-52. (Pubitemid 29084739)
19. Jacobs C, Kayser O, Müller R. (2000). Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharmaceut 196:161-4.
20. Jain D, Panda AK, Majumdar DK. (2005). Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS Pharmscitech 6:100-7.
21. Karn PR, Vanić Z, Pepić I, Skalko-Basnet N. (2011). Mucoadhesive liposomal delivery systems: the choice of coating material. Drug Dev Ind Pharm 37:482-8.
22. Keresztes A, Birkás E, Páhi A, et al. (2011). Pharmacology of a new tritiated endomorphin-2 analog containing the proline mimetic cis-2- aminocyclohexanecarboxylic acid. Peptides 32:722-8.
23. Kim B, Peppas NA. (2003). In vitro release behavior and stability of insulin in complexation hydrogels as oral drug delivery carriers. Int J Pharmaceut 266:29-37. (Pubitemid 37258337)
24. Koda Y, Del borgo M, Wessling ST, et al. (2008). Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem 16:6286-96.
25. Kolter K, Subkowski T, Raditsch M, Schehlmann V. (2003). Use of (meth) acrylic acid copolymers to increase the permeability of mucous membranes. Google Patents.
26. Lopedota A, Trapani A, Cutrignelli A, et al. (2009). The use of Eudragit RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. Eur J Pharmaceut Biopharmaceut 7: 509-20.
27. Mahato RI, Narang AS, Thoma L, Miller DD. (2003). Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20:153-214. (Pubitemid 37237279)
28. Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165-96. (Pubitemid 32324113)
29. Mukherjee S, Ray S, Thakur RS. (2009). Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Ind J Pharmaceut Sci 71:349-58.
30. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharmaceut Biopharmaceut 50:161-77. (Pubitemid 30326695)
31. Müllertz A. (2007). Biorelevant dissolution media. Solvent systems and their selection in pharmaceutics and biopharmaceutics. New York: Springer.
32. Mustata G, Dinh SM. (2006). Approaches to oral drug delivery for challenging molecules. Crit Rev Therapeut Drug Carrier Syst 23: 111-35. (Pubitemid 44403815)
33. Nguyen DA, Fogler HS. (2005). Facilitated diffusion in the dissolution of carboxylic polymers. AIChE J 51:415-25. (Pubitemid 40321674)
34. Olbrich C, Kayser O, Müller RH. (2002). Enzymatic degradation of Dynasan 114 SLN-effect of surfactants and particle size. J Nanoparticle Res 4:121-9.
35. Patravale V, Date AA, Kulkarni R. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharma Pharmacol 56:827-40. (Pubitemid 38885975)
36. Paul W, Sharma CP. (2008). Tricalcium phosphate delayed release formulation for oral delivery of insulin: a proof-of-concept study. J Pharmaceut Sci 97:875-82. (Pubitemid 351293887)
37. Perlikowska R, Fichna J, Wyrebska A, et al. (2009). Design, synthesis and pharmacological characterization of endomorphin analogues with non-cyclic amino acid residues in position 2. Basic Clin Pharmacol Toxicol 106:106-13.
38. Pharmacopeia U. (2005). Chapter 711 Dissolution. Physical Tests 2: 2412-14.
39. Przewlocki R, Przewlocka B. (2001). Opioids in chronic pain. Eur J Pharmacol 429:79-91. (Pubitemid 33043984)
40. Rawat M, Saraf S. (2007). Influence of selected formulation variables on the preparation of enzyme-entrapped eudragit S100 microspheres. AAPS Pharmscitech 8:289-97.
41. Sahlin A, Lodén M, Akerström U, Neimert K. (2008). Topical formulations. EP Patent 1,941,860, A1:1-22.
42. Sakurada S, Watanabe H, Hayashi T, et al. (2002). Endomorphin analogues containing D-Pro(2) discriminate different mu-opioid receptor mediated antinociception in mice. Br J Pharmacol 137: 1143-6.
43. Santos-magalhaes N, Pontes A, Pereira V, Caetano M. (2000). Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules. Int J Pharmaceut 208:71-80.
44. Schubert MA, Müller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharmaceut Biopharmaceut 55: 125-31. (Pubitemid 36120504)
45. Shaji J, Patole V. (2008). Protein and peptide drug delivery: oral approaches. Ind J Pharmaceut Sci 70:269-77.
46. Sharma M, Sharma V, Panda AK, Majumdar DK. (2011). Development of enteric submicron particle formulation of papain for oral delivery. Int J Nanomed 6:2097-111.
47. Sood A, Panchagnula R. (2001). Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev-Columbus 101:3275-304.
48. Staniland P, Chahal S, Tooley I, Sayer R. (2011). Protection against photoageing. Focus Sun Care 3:20-3.
49. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. (2003). Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Rel 86:235-42. (Pubitemid 36084273)
50. Thompson C, Ibie C. (2011). The oral delivery of proteins using interpolymer polyelectrolyte complexes. Therapeut Deliv 2: 1611-31.
51. Tömböly C, Péter A, Tóth G. (2002). In vitro quantitative study of the degradation of endomorphins. Peptides 23:1573-80.
52. Toth I. (1994). A novel chemical approach to drug delivery: lipidic amino acid conjugates. J Drug Target 2:217-39. (Pubitemid 24310625)
53. Varamini P, Mansfeld FM, Blanchfield JT, et al. (2012a). Lipoendomorphin- 1 derivatives with systemic activity against neuropathic pain without producing constipation. PLoS ONE 7:e41909.
54. Varamini P, Mansfeld FM, Blanchfield JT, et al. (2012b). Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J Med Chem 55:5859-67.
55. Varshosaz J, Eskandari S, Tabakhian M. (2010). Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm Dev Technol 15:89-96.
56. Wolfe D, Hao S, Hu J, et al. (2007). Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 133:29-38. (Pubitemid 350138306)
57. Yoo J-W, Giri N, Lee CH. (2011). pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int J Pharmaceut 403:262-7.
58. Yu LX, Amidon GL, Polli JE, et al. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceut Res 19:921-5.
59. Zhuang CY, Li N, Wang M, et al. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharmaceut 394:179-85.
60. zur Mühlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharmaceut Biopharmaceut 45:149-55. (Pubitemid 28167741)